Hepatotoxicity with KRASG12C Inhibitors in NSCLC

Opinion
Video

Dr Narjust Florez discusses the hepatoxicity associated with KRAS G12C inhibitors, noting both adagrasib and sotorasib pose liver damage risks, but real-world data suggests adagrasib may have a lower risk; she emphases the importance of considering other causes of hepatoxicity before attributing it solely to these therapies.

CN_OncView_KRASG12C_NSCLC_Seg06_HEPATOXICITY
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
      Studying How Climate Disaster Responses Impact Post-NSCLC Surgery Survival
      A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
      Hospital Length of Stay After NSCLC Surgery Higher With Wildfire Exposure
      6 experts are featured in this series.
      Future Therapies for ALK+ Metastatic NSCLC
      6 experts are featured in this series.
      Evaluating ALK Inhibitors in Treatment Sequencing and Testing
      6 experts are featured in this series.
      Treatment Strategies in Disease Progression in ALK+ NSCLC
      6 experts are featured in this series.
      Patient Factors Considered when Choosing Treatment Selection
      6 experts are featured in this series.
      KRAS+ NSCLC: Treatment Management Strategies
      6 experts are featured in this series.
      Is There a Role for KRAS Inhibitors in the First-Line Treatment of NSCLC?
      6 experts are featured in this series.
      KRAS G12 Inhibitor Treatment Options
      6 experts are featured in this series.
      Clinical Experience of Lorlatinib ALK+ NSCLC Patients
      Related Content
      Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

      EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC

      Russ Conroy
      April 2nd 2025
      Article

      Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

      The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

      Improving NSCLC Surgery Recovery After Climate Disaster Exposure

      Leticia Nogueira, PhD, MPH
      March 31st 2025
      Podcast

      The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

      Findings from the phase 3 CROWN trial evaluating lorlatinib in ALK-positive non–small cell lung cancer revealed a sustained PFS benefit with the agent.

      Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment

      Roman Fabbricatore
      March 29th 2025
      Article

      Findings from the phase 3 CROWN trial evaluating lorlatinib in ALK-positive non–small cell lung cancer revealed a sustained PFS benefit with the agent.

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      Navigating Management and Dosing Considerations for Amivantamab in NSCLC

      Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
      February 10th 2025
      Podcast

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      CAN-2409/Prodrug Improve OS in ICI-Resistant, Advanced NSCLC

      CAN-2409/Prodrug Improve OS in ICI-Resistant, Advanced NSCLC

      Tim Cortese
      March 27th 2025
      Article

      CAN-2409 plus valacyclovir or acyclovir elicited a median OS of 24.5 months in the overall population of patients who progressed after immune checkpoint inhibitor therapy.

      Ensartinib Yields “Promising” Efficacy in Pretrated METex14–positive NSCLC

      Ensartinib Yields “Promising” Efficacy in Pretrated METex14–positive NSCLC

      Tim Cortese
      March 25th 2025
      Article

      In the phase 2 EMBRACE trial, ensartinib demonstrated an ORR of 53.3%, a DCR of 86.7%, and a tumor shrinkage rate of 33.3% in patients with METex14-positive NSCLC.